Comparative in vitro activity of the new oral cephalosporin BMY-28100
- PMID: 3595580
- DOI: 10.1007/BF02018202
Comparative in vitro activity of the new oral cephalosporin BMY-28100
Abstract
Using a broth microdilution method, the in vitro activity of BMY-28100 against 365 clinical strains of commonly isolated bacteria was determined. BMY-28100 showed good activity against streptococci, methicillin-susceptible staphylococci, Salmonella spp., Shigella spp., and beta-lactamase producing Branhamella catarrhalis and Haemophilus influenzae. Against susceptible strains of these organisms, BMY-28100 showed activity comparable to that of penicillin G, ampicillin, co-trimoxazole, erythromycin, cefaclor, doxycycline and amoxicillin/potassium clavulanate. BMY-28100 had moderate activity against Arizona hinshawii and poor activity against Campylobacter jejuni and Yersinia enterocolitica.
Similar articles
-
Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.Drugs. 1993 Feb;45(2):295-317. doi: 10.2165/00003495-199345020-00008. Drugs. 1993. PMID: 7681376 Review.
-
Comparative antibacterial activity of the new oral cephalosporin BMY-28100.Eur J Clin Microbiol. 1987 Jun;6(3):309-12. doi: 10.1007/BF02017621. Eur J Clin Microbiol. 1987. PMID: 3497804
-
In vitro activity of BMY 28100, a new oral cephalosporin.Eur J Clin Microbiol. 1987 Feb;6(1):111-3. doi: 10.1007/BF02097214. Eur J Clin Microbiol. 1987. PMID: 3494601
-
BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.Diagn Microbiol Infect Dis. 1988 Jan;9(1):11-26. doi: 10.1016/0732-8893(88)90056-9. Diagn Microbiol Infect Dis. 1988. PMID: 3259489
-
Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.Diagn Microbiol Infect Dis. 2009 Jun;64(2):202-12. doi: 10.1016/j.diagmicrobio.2009.01.017. Epub 2009 Mar 25. Diagn Microbiol Infect Dis. 2009. PMID: 19321284 Review.
Cited by
-
Bactericidal activity of BMY-28100 versus amoxicillin/clavulanic acid against Branhamella catarrhalis.Eur J Clin Microbiol Infect Dis. 1988 Jun;7(3):433-4. doi: 10.1007/BF01962359. Eur J Clin Microbiol Infect Dis. 1988. PMID: 3137055 No abstract available.
-
Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.Drugs. 1993 Feb;45(2):295-317. doi: 10.2165/00003495-199345020-00008. Drugs. 1993. PMID: 7681376 Review.
-
In vitro activity and beta-lactamase stability of the oral cephalosporin BMY-28100.Eur J Clin Microbiol. 1987 Oct;6(5):559-63. doi: 10.1007/BF02014246. Eur J Clin Microbiol. 1987. PMID: 3501756
-
Comparative studies of cefprozil in the management of skin and soft-tissue infections.Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):866-71. doi: 10.1007/BF02111354. Eur J Clin Microbiol Infect Dis. 1994. PMID: 7889961 Review.
-
Five-day versus ten-day treatment of acute otitis media with cefprozil.Eur J Clin Microbiol Infect Dis. 1997 Apr;16(4):283-6. doi: 10.1007/BF01695632. Eur J Clin Microbiol Infect Dis. 1997. PMID: 9177961 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous